Performance of a SARS-CoV-2 antigen rapid immunoassay in patients admitted to the emergency department.
Int J Infect Dis
; 110: 135-140, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-1322130
ABSTRACT
OBJECTIVES:
Given the ongoing pandemic emergency, there is a need to identify SARS CoV-2 infection in various community settings. Rapid antigen testing is spreading worldwide, but diagnostic accuracy is extremely variable. Our study compared a microfluidic rapid antigen test with a reference molecular assay in patients admitted to the emergency department (ED) of a general hospital from October 2020 to January 2021.METHODS:
Nasopharyngeal swabs collected in patients with suspected COVID-19 and in patients with no symptoms suggesting COVID-19, but requiring hospitalization, were obtained.RESULTS:
792 patients of median age 71 years were included. With a prevalence of 21%, the results showed 68.7% (95% confidence interval [CI] 60.9-75.5) sensitivity; 95.2% (95% CI 93.1-96.7) specificity; 79.2% (95% CI 71.4-85.3) positive predictive value (PPV); 91.9% (95% CI 89.5-93.9) negative predictive value; 3.8 (95% CI 2.7-5.3) positive likelihood ratio (LR+); and 0.09 (95% CI 0.07-0.1) negative likelihood ratio (LR-). In the symptomatic subgroup, sensitivity increased to 81% (95% CI 70.3-88.6) and PPV to 96.9% (95% CI 88.5-99.5), along with an LR+ of 32 (95% CI 8.2-125.4).CONCLUSIONS:
The new rapid antigen test showed an overall excellent diagnostic performance in a challenging situation, such as that of an ED during the COVID-19 emergency.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Aged
/
Humans
Language:
English
Journal:
Int J Infect Dis
Journal subject:
Communicable Diseases
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS